ClinicalTrials.gg
CompletedNCT03921411Updated Apr 21, 2023Results posted

A Pharmacokinetics and Safety Study of Nemolizumab in Adolescent Participants With Atopic Dermatitis (AD)

A Phase 2 interventional study of Nemolizumab in Atopic Dermatitis, sponsored by Galderma R&D. Completed at 10 sites in United States. Open to participants aged 12 Years to 17 Years. Per ClinicalTrials.gov, last updated 2023-04-21.

Sponsored by Galderma R&D (part of Galderma Group AG) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
12 Years to 17 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing nemolizumab in Dermatitis, Atopic — 3 open to participants now, 3 under way, 1 of them phase 3. nemolizumab · Dermatitis, Atopic.

Enrollment
11th of 14
20 · median 209
Started
2019
with 3 others
Phase 2
7 of 14
1 open now
Registered
3rd of 14
by date
Lead sponsor
12 of 14
Galderma R&D

Among the 14 studies testing nemolizumab in Dermatitis, Atopic, this one is the 11th largest by enrollment, is one of 4 that started in 2019, is one of 7 in phase 2, and was the 3rd registered.

Dermatitis, Atopic

1,594 studies on the registry are indexed under Dermatitis, Atopic; 287 are open to participants now.

Browse Dermatitis, Atopic studies →

Open to participants now

3 of the 14 studies testing nemolizumab in Dermatitis, Atopic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About nemolizumab

nemolizumab: first FDA approval 2024 (NEMLUVIO), first EMA approval 2025. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 194 Dermatitis, Atopic studies recruiting now, 83 (43%) set no upper age limit and 95 (49%) stop at 75 or younger; 94 take children under 18; 51 take healthy volunteers.

This study: 12 Years to 17 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing nemolizumab in Dermatitis, Atopic, or all of them as a file.
02

Study summary

The purpose of this study was to evaluate the pharmacokinetics and safety of nemolizumab in adolescent participants with AD.

03

Conditions studied

  • Atopic Dermatitis

Browse trials for

Keywords

  • Nemolizumab
  • Atopic dermatitis
04

Who can participate

Ages eligible
12 Years to 17 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria

  • Male or female participants ≥ 12 to \< 17 years of age
  • Chronic AD that has been documented for at least 2 years
  • Eczema Area and Severity Index (EASI) score ≥ 16
  • Investigator's Global Assessment (IGA) score ≥ 3
  • AD involvement ≥ 10% of Body Surface Area (BSA)
  • Documented recent history of inadequate response to topical medications
  • Women of must agree to be strictly abstinent or to use an effective and approved method of throughout the study and for 12 weeks after the last study drug injection.

Key Exclusion Criteria

  • Body weight \< 30 kilogram (kg)
  • Cutaneous infection within 1 week or any infection requiring treatment with oral or parenteral antibiotics, antivirals, antiparasitics, or antifungals within 1 week
  • History of (including anaphylaxis) to an immunoglobulin product (plasma-derived or recombinant, example., monoclonal antibody)
  • Any medical or psychological condition, or any laboratory abnormalities that may have put the subject at significant risk according to the investigator's judgment
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (actual)

Study arms

  • Experimental
    Nemolizumab

    Nemolizumab

    Biological: Nemolizumab

Interventions

  • BiologicalNemolizumab

    Participants received subcutaneous (SC) injection of 30 milligram (mg) of Nemolizumab every 4 weeks (Q4W) over a 16-week treatment period, with a loading dose of 60 mg on Day 1.

06

What researchers measure

Primary outcomes

  1. Nemolizumab Serum Concentrations at Week 1-2

    Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

    Time frame: At week 1-2

  2. Nemolizumab Serum Concentrations at Week 4

    Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

    Time frame: At week 4

  3. Nemolizumab Serum Concentrations at Week 8

    Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

    Time frame: At week 8

  4. Nemolizumab Serum Concentrations at Week 12

    Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

    Time frame: At week 12

  5. Nemolizumab Serum Concentrations at Week 16

    Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

    Time frame: At week 16

  6. Nemolizumab Serum Concentrations at Week 24

    Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

    Time frame: At week 24

  7. Apparent Clearance After Extravascular Administration (Cl/F) of Nemolizumab

    CL/F is apparent clearance of the drug from the serum, calculated as the drug dose divided area under the curve from time 0 extrapolated to infinite time \[AUC (0-inf)\].

    Time frame: Baseline to week 24

  8. Apparent Volume of Distribution After Extravascular Administration (Vd/F) of Nemolizumab

    Vd/F was calculated as dose divided by lambda_z \*AUC(0-inf).

    Time frame: Baseline to week 24

  9. Population Lag Time (Tlag)

    Lag time is defined as the time taken for a drug to appear in the systemic circulation following administration. The population Tlag value was estimated for the overall population and was reported in this endpoint.

    Time frame: Baseline to week 24

  10. First Order Constant of Absorption (ka)

    PK of Nemolizumab was evaluated in participants using Ka using PK samples collected on Weeks 1-2, 4, 8, 12, 16 and 24. Ka was evaluated by population PK (popPK) methods and mean and standard from the model has been tabulated.

    Time frame: Baseline to week 24

  11. Maximum Observed Serum Concentration (Cmax) of Nemolizumab

    Cmax was obtained from serum concentration time curve.

    Time frame: Baseline to week 12

  12. Time to Reach Maximum Observed Serum Concentration (Tmax) of Nemolizumab

    Time to reach maximum observed serum concentration (Tmax) for Nemolizumab was derived from serum concentrations versus time data.

    Time frame: Baseline to week 12

  13. Trough Serum Concentration (Ctrough) of Nemolizumab at Week 4

    Ctrough is the concentration prior to study drug administration.

    Time frame: At week 4

  14. Trough Serum Concentration (Ctrough) of Nemolizumab at Week 8

    Ctrough is the concentration prior to study drug administration.

    Time frame: At week 8

  15. Trough Serum Concentration (Ctrough) of Nemolizumab at Week 12

    Ctrough is the concentration prior to study drug administration.

    Time frame: At week 12

  16. Trough Serum Concentration (Ctrough) of Nemolizumab at Week 16

    Ctrough is the concentration prior to study drug administration.

    Time frame: At week 16

  17. Area Under the Serum Concentration-Time Curve From Zero to 4 Week Post-dose (AUC0-4w)

    Area under the drug concentration-time curve from 0 to 4 week post dosing for Nemolizumab. AUC(0-4w) was calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose through 4 weeks post-dose

  18. Area Under the Serum Concentration-Time Curve From Time Zero to 8 Week Post-dose (AUC0-8w)

    Area under the drug concentration-time curve from 0 to 8 week post dosing for Nemolizumab. AUC(0-8w) was calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose through 8 weeks post-dose

  19. Area Under the Serum Concentration-Time Curve From Time Zero to 12 Week Post-dose (AUC0-12w)

    Area under the drug concentration-time curve from 0 to 12 week post dosing for Nemolizumab. AUC(0-12w) was calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose through 12 week post-dose

  20. Area Under the Serum Concentration-Time Curve From Time Zero to 16 Week Post-dose (AUC0-16w)

    Area under the drug concentration-time curve from 0 to 16 week post dosing for Nemolizumab. AUC(0-16w) was calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose through 16 weeks post-dose

  21. Apparent Terminal Half-life (t1/2)

    Apparent Terminal Half-life (t1/2) is the time required for a given drug concentration in the serum to decrease by 50%.

    Time frame: Baseline to week 24

  22. Number of Participants With Treatment-Related Positive Anti-Drug Antibodies (ADA) in Serum at Week 4

    Antidrug antibodies were determined using a validated enzyme-linked immunosorbent assay (ELISA) assay. Number of participants with positive ADA in Serum were reported.

    Time frame: At week 4

  23. Number of Participants With Neutralizing Antibodies

    The number of participants with neutralizing antibodies response at time of baseline up to week 24 has been presented. Neutralizing antibodies response assay result have been only presented for participants with positive anti-drug antibody assay.

    Time frame: Baseline up to Week 24

  24. Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Adverse Event of Special Interests (AESI) and Serious Adverse Events (SAEs)

    An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAE was defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs. An AESI is a noteworthy event for study drug that should be monitored closely and reported immediately. The following AEs will be considered AESIs: Anaphylactic reactions, Acute allergic reactions requiring treatment, Severe injection site reaction, Newly-diagnosed asthma or worsening of asthma, Peripheral edema: limbs, bilateral and Facial edema.

    Time frame: Baseline through week 24

  25. Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 1-2

    The ACT is a participant-completed assessment consisting of 5 questions health survey for measuring asthma control. Each question is answered with a score in a range of 1 to 5 and lower score represents the more severe condition. The scale range for Question 1 is "all the time" (1) to "none of the time" (5); Question 2 range: "more than once a day" (1) to "not at all" (5); Question 3 range: "4 or more nights a week" (1) to "not at all" (5); Question 4 range: "3 or more times per day" (1) to "not at all" (5); Question 5 range: "not controlled at all" (1) to "completely controlled" (5). A total ACT score is obtained as the sum of the 5 individual question scores that is from 5 to 25, where Higher scores mean that asthma is more controlled.

    Time frame: At week 1-2

  26. Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 4

    The ACT is a participant-completed assessment consisting of 5 questions health survey for measuring asthma control. Each question is answered with a score in a range of 1 to 5 and lower score represents the more severe condition. The scale range for Question 1 is "all the time" (1) to "none of the time" (5); Question 2 range: "more than once a day" (1) to "not at all" (5); Question 3 range: "4 or more nights a week" (1) to "not at all" (5); Question 4 range: "3 or more times per day" (1) to "not at all" (5); Question 5 range: "not controlled at all" (1) to "completely controlled" (5). A total ACT score is obtained as the sum of the 5 individual question scores that is from 5 to 25, where Higher scores mean that asthma is more controlled.

    Time frame: At week 4

  27. Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 8

    The ACT is a participant-completed assessment consisting of 5 questions health survey for measuring asthma control. Each question is answered with a score in a range of 1 to 5 and lower score represents the more severe condition. The scale range for Question 1 is "all the time" (1) to "none of the time" (5); Question 2 range: "more than once a day" (1) to "not at all" (5); Question 3 range: "4 or more nights a week" (1) to "not at all" (5); Question 4 range: "3 or more times per day" (1) to "not at all" (5); Question 5 range: "not controlled at all" (1) to "completely controlled" (5). A total ACT score is obtained as the sum of the 5 individual question scores that is from 5 to 25, where Higher scores mean that asthma is more controlled.

    Time frame: At week 8

  28. Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 12

    The ACT is a participant-completed assessment consisting of 5 questions health survey for measuring asthma control. Each question is answered with a score in a range of 1 to 5 and lower score represents the more severe condition. The scale range for Question 1 is "all the time" (1) to "none of the time" (5); Question 2 range: "more than once a day" (1) to "not at all" (5); Question 3 range: "4 or more nights a week" (1) to "not at all" (5); Question 4 range: "3 or more times per day" (1) to "not at all" (5); Question 5 range: "not controlled at all" (1) to "completely controlled" (5). A total ACT score is obtained as the sum of the 5 individual question scores that is from 5 to 25, where Higher scores mean that asthma is more controlled.

    Time frame: At week 12

  29. Number of Participants With Clinically Significant Abnormalities in Physical Examination (PE) Findings

    A complete PE included assessments of the head, ears, eyes, nose, throat, neck (including thyroid), skin/integumentary system, cardiovascular system, respiratory system, gastrointestinal system, musculoskeletal system, lymph nodes, and nervous system. Clinical significance was determined by the investigator.

    Time frame: Baseline up to Week 24

  30. Number of Participants With Clinically Significant Abnormalities in Laboratory Values

    Laboratory investigation included hematology, biochemistry, and urinalysis. Clinical significance was determined by the investigator. The number of participants with clinically significant abnormalities in laboratory parameters were reported.

    Time frame: Baseline up to Week 24

  31. Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Findings at Week 16

    The ECG recordings were obtained after 10 minutes of rest in a semi-supine position. Number of participants with clinically significant change from baseline in ECG findings were reported. Clinically significance was decided by investigator.

    Time frame: At week 16

  32. Number of Participants With Clinically Significant Abnormalities in Vital Signs

    Vital signs included pulse rate, systolic and diastolic blood pressure (after the participant had been sitting for at least 5 minutes), and body temperature. Clinically significance was decided by investigator..

    Time frame: Baseline up to Week 24

  33. Number of Participants With Abnormal Peak Expiratory Flow (PEF) <80% of Predicted Value at Week 1-2

    PEF was the maximum speed of expiration measured using spirometer. A participant took rest just before the measurement. At each time of measurement, a participant expired for at least 6 seconds wherever possible. At each time of measurement, at least 3 readings were obtained, and three readings which were obtained in an appropriate manner were stored. PEF \<80% of predictive value is considered as abnormal.

    Time frame: At week 1-2

  34. Number of Participants With Abnormal Peak Expiratory Flow (PEF) <80% Predicted Value at Week 4

    PEF was the maximum speed of expiration measured using spirometer. A participant took rest just before the measurement. At each time of measurement, a participant expired for at least 6 seconds wherever possible. At each time of measurement, at least 3 readings were obtained, and three readings which were obtained in an appropriate manner were stored. PEF \<80% of predictive value is considered as abnormal.

    Time frame: At week 4

Secondary outcomes

  1. Non-Compartmental Analysis: Area Under the Serum Concentration-time Curve From Time Zero to 4 Weeks Post-dose AUC(0-4w)

    Area under the drug concentration-time curve from 0 to 4 week post dosing for Nemolizumab. AUC(0-4w) was calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose through 4 weeks post-dose

  2. Non-Compartmental Analysis: Area Under the Serum Concentration-Time Curve From Time Zero to 8 Week Post-dose (AUC0-8w)

    Area under the drug concentration-time curve from 0 to 8 week post dosing for Nemolizumab. AUC(0-8w) was calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose through 8 weeks post-dose

  3. Non-Compartmental Analysis: Area Under the Serum Concentration-Time Curve From Time Zero to 12 Week Post-dose (AUC0-12w)

    Area under the drug concentration-time curve from 0 to 12 week post dosing for Nemolizumab. AUC(0-12w) was calculated according to the mixed log-linear trapezoidal rule

    Time frame: Pre-dose through 12 week post-dose

  4. Non-Compartmental Analysis: Area Under the Serum Concentration-Time Curve From Time Zero to 16 Week Post-dose (AUC0-16w)

    Area under the drug concentration-time curve from 0 to 16 week post dosing for Nemolizumab. AUC(0-16w) was calculated according to the mixed log-linear trapezoidal rule.

    Time frame: Pre-dose through 16 weeks post-dose

  5. Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16

    EASI assesses severity and extent of atopic dermatitis (AD) signs through a composite score of erythema, induration/population, excoriation, and lichenification. Each characteristic was assessed for severity on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs. The total EASI score range from 0 to 72 with higher scores representing greater severity of AD.

    Time frame: Baseline, Week 16

  6. Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16

    EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. Each characteristic was assessed for severity on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs. The EASI score can range from 0 to 72 with higher scores representing greater severity of AD.

    Time frame: Baseline, Week 16

  7. Number of Participants Who Achieved Investigator's Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) From Baseline to Week 16

    IGA is a 5-point scale used by the investigator or trained designee to evaluate the global severity of AD. Ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), where higher score indicated higher severity. IGA success is defined as participants with 0 (clear) or 1 (almost clear) and at least 2 -grade improvement from baseline. Number of Participants who achieved Investigator's Global Assessment (IGA) Success from baseline to week 16 were reported.

    Time frame: Baseline to Week 16

  8. Change From Baseline in the Percentage of Body Surface Area (BSA) Involvement by Atopic Dermatitis (AD) at Each Visit up to Week 24

    BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections.

    Time frame: Baseline, Week 1-2, 4, 8, 12, 14, 16 and 24

  9. Absolute Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (NRS) Score at Week 16

    Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

    Time frame: Baseline, Week 16

  10. Percent Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (NRS) Score at Week 16

    Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

    Time frame: Baseline, Week 16

  11. Absolute Change From Baseline in Weekly Average of Average Pruritus Numeric Rating Scale (NRS) Score at Week 16

    Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

    Time frame: Baseline, Week 16

  12. Percent Change From Baseline in Weekly Average of Average Pruritus Numeric Rating Scale (NRS) Score at Week 16

    Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

    Time frame: Baseline, Week 16

  13. Absolute Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) Score at Week 16

    The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicate worse outcome.

    Time frame: Baseline, Week 16

  14. Percent Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) Score at Week 16

    The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicate worse outcome.

    Time frame: Baseline, Week 16

  15. Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 16

    Scoring Atopic Dermatitis (SCORAD) is a validated measure commonly used to assess the severity and the extent of AD signs and symptoms. SCORAD is a clinical tool for assessing the severity and the extent of AD signs and symptoms. Extent and intensity of six types of basic lesions (erythema/darkening, edema/papule, oozing/crusting, excoriation, lichenification/prurigo and dryness) and symptoms (itching and loss of sleep) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

    Time frame: Baseline, Week 16

  16. Number of Topical Atopic Dermatitis Medication-Free Days Through Week 24

    Number of topical AD medication-free days through Week 16 was calculated as the number of days that a participant used neither topical corticosteroid (TCS)/ topical calcineurin inhibitors (TCI) nor system rescue therapy divided by the study days.

    Time frame: Baseline through Week 24

  17. Dermatology Life Quality Index (DLQI) For Participants > 16 Years of Age at Baseline and Week 16

    The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participants were rate each question ranging from 0 (not at all) to 3 (very much) and overall score ranges from 0 to 30. A higher total score indicates a poorer quality of life (QoL).

    Time frame: Baseline, Week 16

  18. Children's Dermatology Life Quality Index (cDLQI) For Participants 12-16 Years of Age at Baseline and Week 16

    The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participants were rate each question ranging from 0 (not at all) to 3 (very much) and overall score ranges from 0 to 30. A higher total score indicates a poorer quality of life (QoL).

    Time frame: Baseline, Week 16

07

Results

Posted Apr 21, 2023

Participant flow

A total of 31 participants were screened, of which 20 were enrolled and 18 participants were treated with study drug.

Participant flow — Overall Study
MilestoneNemolizumab
Started20
Treated18
Completed15
Not completed5
Withdrew: Withdrawal by subject1
Withdrew: Protocol deviation2
Withdrew: Enrolled, but never treated2

Outcome measures

PrimaryNemolizumab Serum Concentrations at Week 1-2

Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

Time frame:
At week 1-2
Reported as:
Mean · nanogram per milliliter (ng/mL)
Nemolizumab Serum Concentrations at Week 1-2
nanogram per milliliter (ng/mL)Nemolizumab
Nemolizumab Serum Concentrations at Week 1-26478.8 ± 2393.11
PrimaryNemolizumab Serum Concentrations at Week 4

Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

Time frame:
At week 4
Reported as:
Mean · ng/mL
Nemolizumab Serum Concentrations at Week 4
ng/mLNemolizumab
Nemolizumab Serum Concentrations at Week 42935.3 ± 1029.41
PrimaryNemolizumab Serum Concentrations at Week 8

Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

Time frame:
At week 8
Reported as:
Mean · ng/mL
Nemolizumab Serum Concentrations at Week 8
ng/mLNemolizumab
Nemolizumab Serum Concentrations at Week 83292.3 ± 2017.83
PrimaryNemolizumab Serum Concentrations at Week 12

Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

Time frame:
At week 12
Reported as:
Mean · ng/mL
Nemolizumab Serum Concentrations at Week 12
ng/mLNemolizumab
Nemolizumab Serum Concentrations at Week 123221.6 ± 1781.15
PrimaryNemolizumab Serum Concentrations at Week 16

Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

Time frame:
At week 16
Reported as:
Mean · ng/mL
Nemolizumab Serum Concentrations at Week 16
ng/mLNemolizumab
Nemolizumab Serum Concentrations at Week 163010.0 ± 1131.81
PrimaryNemolizumab Serum Concentrations at Week 24

Serum concentrations of Nemolizumab were analyzed using validated enzyme linked immunosorbent assay (ELISA).

Time frame:
At week 24
Reported as:
Mean · ng/mL
Nemolizumab Serum Concentrations at Week 24
ng/mLNemolizumab
Nemolizumab Serum Concentrations at Week 24473.9 ± 333.72
PrimaryApparent Clearance After Extravascular Administration (Cl/F) of Nemolizumab

CL/F is apparent clearance of the drug from the serum, calculated as the drug dose divided area under the curve from time 0 extrapolated to infinite time \[AUC (0-inf)\].

Time frame:
Baseline to week 24
Reported as:
Mean · liter/day (L/day)
Apparent Clearance After Extravascular Administration (Cl/F) of Nemolizumab
liter/day (L/day)Nemolizumab
Apparent Clearance After Extravascular Administration (Cl/F) of Nemolizumab0.325 ± 0.153
PrimaryApparent Volume of Distribution After Extravascular Administration (Vd/F) of Nemolizumab

Vd/F was calculated as dose divided by lambda_z \*AUC(0-inf).

Time frame:
Baseline to week 24
Reported as:
Mean · liter
Apparent Volume of Distribution After Extravascular Administration (Vd/F) of Nemolizumab
literNemolizumab
Apparent Volume of Distribution After Extravascular Administration (Vd/F) of Nemolizumab7.15 ± 2.24
PrimaryPopulation Lag Time (Tlag)

Lag time is defined as the time taken for a drug to appear in the systemic circulation following administration. The population Tlag value was estimated for the overall population and was reported in this endpoint.

Time frame:
Baseline to week 24
Reported as:
Mean · hours
Population Lag Time (Tlag)
hoursNemolizumab
Population Lag Time (Tlag)1.0728 ± 0
PrimaryFirst Order Constant of Absorption (ka)

PK of Nemolizumab was evaluated in participants using Ka using PK samples collected on Weeks 1-2, 4, 8, 12, 16 and 24. Ka was evaluated by population PK (popPK) methods and mean and standard from the model has been tabulated.

Time frame:
Baseline to week 24
Reported as:
Mean · 1/day
First Order Constant of Absorption (ka)
1/dayNemolizumab
First Order Constant of Absorption (ka)0.402 ± 0.145
PrimaryMaximum Observed Serum Concentration (Cmax) of Nemolizumab

Cmax was obtained from serum concentration time curve.

Time frame:
Baseline to week 12
Reported as:
Mean · ng/mL
Maximum Observed Serum Concentration (Cmax) of Nemolizumab
ng/mLNemolizumab
Maximum Observed Serum Concentration (Cmax) of Nemolizumab5975.5 ± 2175.2
PrimaryTime to Reach Maximum Observed Serum Concentration (Tmax) of Nemolizumab

Time to reach maximum observed serum concentration (Tmax) for Nemolizumab was derived from serum concentrations versus time data.

Time frame:
Baseline to week 12
Reported as:
Mean · days
Time to Reach Maximum Observed Serum Concentration (Tmax) of Nemolizumab
daysNemolizumab
Time to Reach Maximum Observed Serum Concentration (Tmax) of Nemolizumab5.862 ± 1.669
PrimaryTrough Serum Concentration (Ctrough) of Nemolizumab at Week 4

Ctrough is the concentration prior to study drug administration.

Time frame:
At week 4
Reported as:
Mean · ng/mL
Trough Serum Concentration (Ctrough) of Nemolizumab at Week 4
ng/mLNemolizumab
Trough Serum Concentration (Ctrough) of Nemolizumab at Week 43271.859 ± 1268.612
PrimaryTrough Serum Concentration (Ctrough) of Nemolizumab at Week 8

Ctrough is the concentration prior to study drug administration.

Time frame:
At week 8
Reported as:
Mean · ng/mL
Trough Serum Concentration (Ctrough) of Nemolizumab at Week 8
ng/mLNemolizumab
Trough Serum Concentration (Ctrough) of Nemolizumab at Week 83056.496 ± 1367.884
PrimaryTrough Serum Concentration (Ctrough) of Nemolizumab at Week 12

Ctrough is the concentration prior to study drug administration.

Time frame:
At week 12
Reported as:
Mean · ng/mL
Trough Serum Concentration (Ctrough) of Nemolizumab at Week 12
ng/mLNemolizumab
Trough Serum Concentration (Ctrough) of Nemolizumab at Week 122886.796 ± 1441.998
PrimaryTrough Serum Concentration (Ctrough) of Nemolizumab at Week 16

Ctrough is the concentration prior to study drug administration.

Time frame:
At week 16
Reported as:
Mean · ng/mL
Trough Serum Concentration (Ctrough) of Nemolizumab at Week 16
ng/mLNemolizumab
Trough Serum Concentration (Ctrough) of Nemolizumab at Week 162981.792 ± 1166.871
PrimaryArea Under the Serum Concentration-Time Curve From Zero to 4 Week Post-dose (AUC0-4w)

Area under the drug concentration-time curve from 0 to 4 week post dosing for Nemolizumab. AUC(0-4w) was calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose through 4 weeks post-dose
Reported as:
Mean · nanogram*day per milliliter (ng*day/mL)
Area Under the Serum Concentration-Time Curve From Zero to 4 Week Post-dose (AUC0-4w)
nanogram*day per milliliter (ng*day/mL)Nemolizumab
Area Under the Serum Concentration-Time Curve From Zero to 4 Week Post-dose (AUC0-4w)144046.235 ± 50800.805
PrimaryArea Under the Serum Concentration-Time Curve From Time Zero to 8 Week Post-dose (AUC0-8w)

Area under the drug concentration-time curve from 0 to 8 week post dosing for Nemolizumab. AUC(0-8w) was calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose through 8 weeks post-dose
Reported as:
Mean · ng*day/mL
Area Under the Serum Concentration-Time Curve From Time Zero to 8 Week Post-dose (AUC0-8w)
ng*day/mLNemolizumab
Area Under the Serum Concentration-Time Curve From Time Zero to 8 Week Post-dose (AUC0-8w)284397.143 ± 97105.285
PrimaryArea Under the Serum Concentration-Time Curve From Time Zero to 12 Week Post-dose (AUC0-12w)

Area under the drug concentration-time curve from 0 to 12 week post dosing for Nemolizumab. AUC(0-12w) was calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose through 12 week post-dose
Reported as:
Mean · ng*day/mL
Area Under the Serum Concentration-Time Curve From Time Zero to 12 Week Post-dose (AUC0-12w)
ng*day/mLNemolizumab
Area Under the Serum Concentration-Time Curve From Time Zero to 12 Week Post-dose (AUC0-12w)411707.857 ± 142851.408
PrimaryArea Under the Serum Concentration-Time Curve From Time Zero to 16 Week Post-dose (AUC0-16w)

Area under the drug concentration-time curve from 0 to 16 week post dosing for Nemolizumab. AUC(0-16w) was calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose through 16 weeks post-dose
Reported as:
Mean · ng*day/mL
Area Under the Serum Concentration-Time Curve From Time Zero to 16 Week Post-dose (AUC0-16w)
ng*day/mLNemolizumab
Area Under the Serum Concentration-Time Curve From Time Zero to 16 Week Post-dose (AUC0-16w)549489.167 ± 184483.765
PrimaryApparent Terminal Half-life (t1/2)

Apparent Terminal Half-life (t1/2) is the time required for a given drug concentration in the serum to decrease by 50%.

Time frame:
Baseline to week 24
Reported as:
Mean · day
Apparent Terminal Half-life (t1/2)
dayNemolizumab
Apparent Terminal Half-life (t1/2)16.666 ± 4.115
PrimaryNumber of Participants With Treatment-Related Positive Anti-Drug Antibodies (ADA) in Serum at Week 4

Antidrug antibodies were determined using a validated enzyme-linked immunosorbent assay (ELISA) assay. Number of participants with positive ADA in Serum were reported.

Time frame:
At week 4
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Related Positive Anti-Drug Antibodies (ADA) in Serum at Week 4
ParticipantsNemolizumab
Number of Participants With Treatment-Related Positive Anti-Drug Antibodies (ADA) in Serum at Week 41
PrimaryNumber of Participants With Neutralizing Antibodies

The number of participants with neutralizing antibodies response at time of baseline up to week 24 has been presented. Neutralizing antibodies response assay result have been only presented for participants with positive anti-drug antibody assay.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Neutralizing Antibodies
ParticipantsNemolizumab
Number of Participants With Neutralizing Antibodies0
PrimaryNumber of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Adverse Event of Special Interests (AESI) and Serious Adverse Events (SAEs)

An adverse event (AE) is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. SAEs is any AE that resulted in death, life threatening, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, is a congenital anomaly/birth defect in offspring of a study participant, is an important medical event that may jeopardize the participant or may require medical intervention. TEAE was defined as AEs starting/worsening after first intake of the study drug. TEAEs included both Serious TEAEs and non-serious TEAEs. An AESI is a noteworthy event for study drug that should be monitored closely and reported immediately. The following AEs will be considered AESIs: Anaphylactic reactions, Acute allergic reactions requiring treatment, Severe injection site reaction, Newly-diagnosed asthma or worsening of asthma, Peripheral edema: limbs, bilateral and Facial edema.

Time frame:
Baseline through week 24
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Adverse Events (TEAEs), Treatment-Emergent Adverse Event of Special Interests (AESI) and Serious Adverse Events (SAEs)
ParticipantsNemolizumab
TEAEs6
TE-AESIs2
SAEs2
PrimaryNumber of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 1-2

The ACT is a participant-completed assessment consisting of 5 questions health survey for measuring asthma control. Each question is answered with a score in a range of 1 to 5 and lower score represents the more severe condition. The scale range for Question 1 is "all the time" (1) to "none of the time" (5); Question 2 range: "more than once a day" (1) to "not at all" (5); Question 3 range: "4 or more nights a week" (1) to "not at all" (5); Question 4 range: "3 or more times per day" (1) to "not at all" (5); Question 5 range: "not controlled at all" (1) to "completely controlled" (5). A total ACT score is obtained as the sum of the 5 individual question scores that is from 5 to 25, where Higher scores mean that asthma is more controlled.

Time frame:
At week 1-2
Reported as:
Count of participants · Participants
Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 1-2
ParticipantsNemolizumab
Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 1-20
PrimaryNumber of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 4

The ACT is a participant-completed assessment consisting of 5 questions health survey for measuring asthma control. Each question is answered with a score in a range of 1 to 5 and lower score represents the more severe condition. The scale range for Question 1 is "all the time" (1) to "none of the time" (5); Question 2 range: "more than once a day" (1) to "not at all" (5); Question 3 range: "4 or more nights a week" (1) to "not at all" (5); Question 4 range: "3 or more times per day" (1) to "not at all" (5); Question 5 range: "not controlled at all" (1) to "completely controlled" (5). A total ACT score is obtained as the sum of the 5 individual question scores that is from 5 to 25, where Higher scores mean that asthma is more controlled.

Time frame:
At week 4
Reported as:
Count of participants · Participants
Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 4
ParticipantsNemolizumab
Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 40
PrimaryNumber of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 8

The ACT is a participant-completed assessment consisting of 5 questions health survey for measuring asthma control. Each question is answered with a score in a range of 1 to 5 and lower score represents the more severe condition. The scale range for Question 1 is "all the time" (1) to "none of the time" (5); Question 2 range: "more than once a day" (1) to "not at all" (5); Question 3 range: "4 or more nights a week" (1) to "not at all" (5); Question 4 range: "3 or more times per day" (1) to "not at all" (5); Question 5 range: "not controlled at all" (1) to "completely controlled" (5). A total ACT score is obtained as the sum of the 5 individual question scores that is from 5 to 25, where Higher scores mean that asthma is more controlled.

Time frame:
At week 8
Reported as:
Count of participants · Participants
Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 8
ParticipantsNemolizumab
Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 80
PrimaryNumber of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 12

The ACT is a participant-completed assessment consisting of 5 questions health survey for measuring asthma control. Each question is answered with a score in a range of 1 to 5 and lower score represents the more severe condition. The scale range for Question 1 is "all the time" (1) to "none of the time" (5); Question 2 range: "more than once a day" (1) to "not at all" (5); Question 3 range: "4 or more nights a week" (1) to "not at all" (5); Question 4 range: "3 or more times per day" (1) to "not at all" (5); Question 5 range: "not controlled at all" (1) to "completely controlled" (5). A total ACT score is obtained as the sum of the 5 individual question scores that is from 5 to 25, where Higher scores mean that asthma is more controlled.

Time frame:
At week 12
Reported as:
Count of participants · Participants
Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 12
ParticipantsNemolizumab
Number of Participants With Asthma Control Test (ACT) Score Less Than or Equal to (=<) 19 at Week 121
PrimaryNumber of Participants With Clinically Significant Abnormalities in Physical Examination (PE) Findings

A complete PE included assessments of the head, ears, eyes, nose, throat, neck (including thyroid), skin/integumentary system, cardiovascular system, respiratory system, gastrointestinal system, musculoskeletal system, lymph nodes, and nervous system. Clinical significance was determined by the investigator.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Physical Examination (PE) Findings
ParticipantsNemolizumab
Number of Participants With Clinically Significant Abnormalities in Physical Examination (PE) Findings2
PrimaryNumber of Participants With Clinically Significant Abnormalities in Laboratory Values

Laboratory investigation included hematology, biochemistry, and urinalysis. Clinical significance was determined by the investigator. The number of participants with clinically significant abnormalities in laboratory parameters were reported.

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Laboratory Values
ParticipantsNemolizumab
Hematology6
Biochemistry5
Urinalyses0
PrimaryNumber of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Findings at Week 16

The ECG recordings were obtained after 10 minutes of rest in a semi-supine position. Number of participants with clinically significant change from baseline in ECG findings were reported. Clinically significance was decided by investigator.

Time frame:
At week 16
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Findings at Week 16
ParticipantsNemolizumab
Number of Participants With Clinically Significant Abnormalities in Electrocardiogram (ECG) Findings at Week 160
PrimaryNumber of Participants With Clinically Significant Abnormalities in Vital Signs

Vital signs included pulse rate, systolic and diastolic blood pressure (after the participant had been sitting for at least 5 minutes), and body temperature. Clinically significance was decided by investigator..

Time frame:
Baseline up to Week 24
Reported as:
Count of participants · Participants
Number of Participants With Clinically Significant Abnormalities in Vital Signs
ParticipantsNemolizumab
Number of Participants With Clinically Significant Abnormalities in Vital Signs5
PrimaryNumber of Participants With Abnormal Peak Expiratory Flow (PEF) <80% of Predicted Value at Week 1-2

PEF was the maximum speed of expiration measured using spirometer. A participant took rest just before the measurement. At each time of measurement, a participant expired for at least 6 seconds wherever possible. At each time of measurement, at least 3 readings were obtained, and three readings which were obtained in an appropriate manner were stored. PEF \<80% of predictive value is considered as abnormal.

Time frame:
At week 1-2
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Peak Expiratory Flow (PEF) <80% of Predicted Value at Week 1-2
ParticipantsNemolizumab
Number of Participants With Abnormal Peak Expiratory Flow (PEF) <80% of Predicted Value at Week 1-21
PrimaryNumber of Participants With Abnormal Peak Expiratory Flow (PEF) <80% Predicted Value at Week 4

PEF was the maximum speed of expiration measured using spirometer. A participant took rest just before the measurement. At each time of measurement, a participant expired for at least 6 seconds wherever possible. At each time of measurement, at least 3 readings were obtained, and three readings which were obtained in an appropriate manner were stored. PEF \<80% of predictive value is considered as abnormal.

Time frame:
At week 4
Reported as:
Count of participants · Participants
Number of Participants With Abnormal Peak Expiratory Flow (PEF) <80% Predicted Value at Week 4
ParticipantsNemolizumab
Number of Participants With Abnormal Peak Expiratory Flow (PEF) <80% Predicted Value at Week 41
SecondaryNon-Compartmental Analysis: Area Under the Serum Concentration-time Curve From Time Zero to 4 Weeks Post-dose AUC(0-4w)

Area under the drug concentration-time curve from 0 to 4 week post dosing for Nemolizumab. AUC(0-4w) was calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose through 4 weeks post-dose
Reported as:
Mean · ng*day/mL
Non-Compartmental Analysis: Area Under the Serum Concentration-time Curve From Time Zero to 4 Weeks Post-dose AUC(0-4w)
ng*day/mLNemolizumab
Non-Compartmental Analysis: Area Under the Serum Concentration-time Curve From Time Zero to 4 Weeks Post-dose AUC(0-4w)122286.736 ± 44081.623
SecondaryNon-Compartmental Analysis: Area Under the Serum Concentration-Time Curve From Time Zero to 8 Week Post-dose (AUC0-8w)

Area under the drug concentration-time curve from 0 to 8 week post dosing for Nemolizumab. AUC(0-8w) was calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose through 8 weeks post-dose
Reported as:
Mean · ng*day/mL
Non-Compartmental Analysis: Area Under the Serum Concentration-Time Curve From Time Zero to 8 Week Post-dose (AUC0-8w)
ng*day/mLNemolizumab
Non-Compartmental Analysis: Area Under the Serum Concentration-Time Curve From Time Zero to 8 Week Post-dose (AUC0-8w)233258.841 ± 80113.408
SecondaryNon-Compartmental Analysis: Area Under the Serum Concentration-Time Curve From Time Zero to 12 Week Post-dose (AUC0-12w)

Area under the drug concentration-time curve from 0 to 12 week post dosing for Nemolizumab. AUC(0-12w) was calculated according to the mixed log-linear trapezoidal rule

Time frame:
Pre-dose through 12 week post-dose
Reported as:
Mean · ng*day/mL
Non-Compartmental Analysis: Area Under the Serum Concentration-Time Curve From Time Zero to 12 Week Post-dose (AUC0-12w)
ng*day/mLNemolizumab
Non-Compartmental Analysis: Area Under the Serum Concentration-Time Curve From Time Zero to 12 Week Post-dose (AUC0-12w)332928.434 ± 121739.832
SecondaryNon-Compartmental Analysis: Area Under the Serum Concentration-Time Curve From Time Zero to 16 Week Post-dose (AUC0-16w)

Area under the drug concentration-time curve from 0 to 16 week post dosing for Nemolizumab. AUC(0-16w) was calculated according to the mixed log-linear trapezoidal rule.

Time frame:
Pre-dose through 16 weeks post-dose
Reported as:
Mean · ng*day/mL
Non-Compartmental Analysis: Area Under the Serum Concentration-Time Curve From Time Zero to 16 Week Post-dose (AUC0-16w)
ng*day/mLNemolizumab
Non-Compartmental Analysis: Area Under the Serum Concentration-Time Curve From Time Zero to 16 Week Post-dose (AUC0-16w)372858.017 ± 149908.126
SecondaryAbsolute Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16

EASI assesses severity and extent of atopic dermatitis (AD) signs through a composite score of erythema, induration/population, excoriation, and lichenification. Each characteristic was assessed for severity on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs. The total EASI score range from 0 to 72 with higher scores representing greater severity of AD.

Time frame:
Baseline, Week 16
Reported as:
Mean · units on a scale
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16
units on a scaleNemolizumab
Absolute Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16-15.994 ± 9.9413
SecondaryPercent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16

EASI assesses severity and extent of AD signs through a composite score of erythema, induration/population, excoriation, and lichenification. Each characteristic was assessed for severity on a scale of 0 (absent) to 3 (severe) for each of the 4 body areas: head/neck, trunk, upper limbs, and lower limbs. The EASI score can range from 0 to 72 with higher scores representing greater severity of AD.

Time frame:
Baseline, Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16
Percent changeNemolizumab
Percent Change From Baseline in Eczema Area and Severity Index (EASI) Score at Week 16-66.52 ± 32.461
SecondaryNumber of Participants Who Achieved Investigator's Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) From Baseline to Week 16

IGA is a 5-point scale used by the investigator or trained designee to evaluate the global severity of AD. Ranging from (0 = clear; 1 = almost clear; 2 = mild; 3 = moderate; 4 = severe), where higher score indicated higher severity. IGA success is defined as participants with 0 (clear) or 1 (almost clear) and at least 2 -grade improvement from baseline. Number of Participants who achieved Investigator's Global Assessment (IGA) Success from baseline to week 16 were reported.

Time frame:
Baseline to Week 16
Reported as:
Count of participants · Participants
Number of Participants Who Achieved Investigator's Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) From Baseline to Week 16
ParticipantsNemolizumab
Number of Participants Who Achieved Investigator's Global Assessment (IGA) Success (Defined as IGA 0 [Clear] or 1 [Almost Clear]) From Baseline to Week 167
SecondaryChange From Baseline in the Percentage of Body Surface Area (BSA) Involvement by Atopic Dermatitis (AD) at Each Visit up to Week 24

BSA affected by AD was assessed for each section of the body (the possible highest score for each region was: head and neck \[9%\], anterior trunk \[18%\], back \[18%\], upper limbs \[18%\], lower limbs \[36%\], and genitals \[1%\]) and reported as a percentage of all major body sections combined. The reported percentage of BSA was combined percentage of all major body sections.

Time frame:
Baseline, Week 1-2, 4, 8, 12, 14, 16 and 24
Reported as:
Mean · Percentage of BSA
Change From Baseline in the Percentage of Body Surface Area (BSA) Involvement by Atopic Dermatitis (AD) at Each Visit up to Week 24
Percentage of BSANemolizumab
Week 1 to 2-1.9 ± 6.33
Week 4-7.1 ± 15.90
Week 8-11.2 ± 15.48
Week 12-17.2 ± 17.94
Week 16-19.9 ± 17.04
Week 24-14.7 ± 17.88
SecondaryAbsolute Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (NRS) Score at Week 16

Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (NRS) Score at Week 16
score on a scaleNemolizumab
Absolute Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (NRS) Score at Week 16-3.122 ± 2.8216
SecondaryPercent Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (NRS) Score at Week 16

Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

Time frame:
Baseline, Week 16
Reported as:
Mean · Percent of change
Percent Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (NRS) Score at Week 16
Percent of changeNemolizumab
Percent Change From Baseline in Weekly Average of Peak Pruritus Numeric Rating Scale (NRS) Score at Week 16-43.21 ± 36.970
SecondaryAbsolute Change From Baseline in Weekly Average of Average Pruritus Numeric Rating Scale (NRS) Score at Week 16

Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Weekly Average of Average Pruritus Numeric Rating Scale (NRS) Score at Week 16
score on a scaleNemolizumab
Absolute Change From Baseline in Weekly Average of Average Pruritus Numeric Rating Scale (NRS) Score at Week 16-2.610 ± 2.6148
SecondaryPercent Change From Baseline in Weekly Average of Average Pruritus Numeric Rating Scale (NRS) Score at Week 16

Pruritus NRS is a scale that was used by the participants to report the intensity of their pruritus (itch) during the last 24 hours. Participants were asked the following question: how would a participant rate his itch at the worst moment during the previous 24 hours (for maximum itch intensity on a scale of 0 - 10 \[0 = no itch; 10 = worst itch imaginable\]), higher scores indicated greater severity.

Time frame:
Baseline, Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Weekly Average of Average Pruritus Numeric Rating Scale (NRS) Score at Week 16
Percent changeNemolizumab
Percent Change From Baseline in Weekly Average of Average Pruritus Numeric Rating Scale (NRS) Score at Week 16-40.85 ± 37.293
SecondaryAbsolute Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) Score at Week 16

The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicate worse outcome.

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Absolute Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) Score at Week 16
score on a scaleNemolizumab
Absolute Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) Score at Week 16-3.050 ± 3.2367
SecondaryPercent Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) Score at Week 16

The sleep disturbance NRS is a scale used by the participants to report the degree of their sleep loss related to AD. Participants were asked the following questions in their local language: how would you rate your sleep last night? On a scale of 0 to 10, with 0 being 'no sleep loss related to signs/symptoms of AD' and 10 being 'I cannot sleep at all due to the signs/symptoms of AD'. Higher scores indicate worse outcome.

Time frame:
Baseline, Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) Score at Week 16
Percent changeNemolizumab
Percent Change From Baseline in Weekly Average Sleep Disturbance Numeric Rating Scale (NRS) Score at Week 16-53.51 ± 47.782
SecondaryPercent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 16

Scoring Atopic Dermatitis (SCORAD) is a validated measure commonly used to assess the severity and the extent of AD signs and symptoms. SCORAD is a clinical tool for assessing the severity and the extent of AD signs and symptoms. Extent and intensity of six types of basic lesions (erythema/darkening, edema/papule, oozing/crusting, excoriation, lichenification/prurigo and dryness) and symptoms (itching and loss of sleep) were assessed and scored. Total score ranges from 0 (absent disease) to 103 (severe disease).

Time frame:
Baseline, Week 16
Reported as:
Mean · Percent change
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 16
Percent changeNemolizumab
Percent Change From Baseline in SCORing Atopic Dermatitis (SCORAD) Score at Week 16-50.08 ± 26.925
SecondaryNumber of Topical Atopic Dermatitis Medication-Free Days Through Week 24

Number of topical AD medication-free days through Week 16 was calculated as the number of days that a participant used neither topical corticosteroid (TCS)/ topical calcineurin inhibitors (TCI) nor system rescue therapy divided by the study days.

Time frame:
Baseline through Week 24
Reported as:
Mean · Days
Number of Topical Atopic Dermatitis Medication-Free Days Through Week 24
DaysNemolizumab
Baseline to Week 1-23.5 ± 2.25
Week 1-2 to Week 47.5 ± 4.87
Week 4 to Week 812.1 ± 7.20
Week 8 to Week 129.7 ± 5.96
Week 12 to Week 1610.7 ± 5.82
Week 16 to Week 2423.4 ± 11.88
SecondaryDermatology Life Quality Index (DLQI) For Participants > 16 Years of Age at Baseline and Week 16

The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participants were rate each question ranging from 0 (not at all) to 3 (very much) and overall score ranges from 0 to 30. A higher total score indicates a poorer quality of life (QoL).

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Dermatology Life Quality Index (DLQI) For Participants > 16 Years of Age at Baseline and Week 16
score on a scaleNemolizumab
Baseline11.8 ± 3.11
Week 163.0 ± 2.58
SecondaryChildren's Dermatology Life Quality Index (cDLQI) For Participants 12-16 Years of Age at Baseline and Week 16

The DLQI is a validated 10-item questionnaire covering domains including symptoms/feelings, daily activities, leisure, work/school, personal relationships, and treatment. The participants were rate each question ranging from 0 (not at all) to 3 (very much) and overall score ranges from 0 to 30. A higher total score indicates a poorer quality of life (QoL).

Time frame:
Baseline, Week 16
Reported as:
Mean · score on a scale
Children's Dermatology Life Quality Index (cDLQI) For Participants 12-16 Years of Age at Baseline and Week 16
score on a scaleNemolizumab
Baseline10.6 ± 5.42
Week 166.2 ± 5.29

Adverse events

Collected over Baseline through Week 24. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Nemolizumab0/18 (0%)2/18 (11.1%)6/18 (33.3%)
Most frequent serious events
Most frequent serious events
EventNemolizumab
Oedema peripheralGeneral disorders1/18
Eczema infectedInfections and infestations1/18
Staphylococcus skin infectionInfections and infestations1/18
Most frequent other events
Most frequent other events
EventNemolizumab
Oedema peripheralGeneral disorders1/18
FatigueGeneral disorders1/18
BronchitisInfections and infestations1/18
Rash pustularInfections and infestations1/18
Upper respiratory tract infectionInfections and infestations1/18
Arthropod biteInjury, poisoning and procedural complications1/18
Blood creatine phosphokinase increasedInvestigations1/18
Pain in extremityMusculoskeletal and connective tissue disorders1/18
DepressionPsychiatric disorders1/18
Dermatitis atopicSkin and subcutaneous tissue disorders1/18

Baseline characteristics

Intent-to-treat (ITT) population included all enrolled participants who signed informed consent form.

Age, Continuous
Age, Continuous(Years)Nemolizumab
Mean14.8 ± 1.59
Sex: Female, Male
Sex: Female, Male(Participants)Nemolizumab
Female12
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Nemolizumab
Hispanic or Latino4
Not Hispanic or Latino16
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Nemolizumab
Asian2
Black or African American10
White7
Other: Hispanic1
08

Study locations

10 sites
  • Galderma Investigational Site
    Fountain Valley, California 92708, United States
  • Galderma Investigational Site
    Fremont, California 94538, United States
  • Galderma Investigational Site
    Jacksonville, Florida 32256, United States
  • Galderma Investigational Site
    Tampa, Florida 33607, United States
  • Galderma Investigational Site
    Columbus, Georgia 31904, United States
  • Galderma Investigational Site
    Sandy Springs, Georgia 30128, United States
  • Galderma Investigational Site
    Gresham, Oregon 97030, United States
  • Galderma Investigational Site
    Dallas, Texas 75230-5806, United States
  • Galderma Investigational Site
    Frisco, Texas 75034, United States
  • Galderma Investigational Site
    Richmond, Virginia 23220, United States
09

References and documents

Publications

  • Sidbury R, Alpizar S, Laquer V, Dhawan S, Abramovits W, Loprete L, Krishnaswamy JK, Ahmad F, Jabbar-Lopez Z, Piketty C. Pharmacokinetics, Safety, Efficacy, and Biomarker Profiles During Nemolizumab Treatment of Atopic Dermatitis in Adolescents. Dermatol Ther (Heidelb). 2022 Mar;12(3):631-642. doi: 10.1007/s13555-021-00678-7. Epub 2022 Jan 28. PubMed 35088348 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2019 to primary completion in Aug 2020, 16 months.

Results were first posted in Apr 2023, 2 years 8 months after primary completion. A results delay was requested in Aug 2021.

Of 196 industry-sponsored phase 2 interventional studies under Dermatitis, Atopic, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 17. This study's 16 months is above that.

Counting every sponsor, half of 224 studies reached it within 14 months; a quarter within 10 and three quarters within 19.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 29, 2019
First posted
Apr 19, 2019
StartActual
Apr 9, 2019
Primary completionActual
Aug 19, 2020
CompletionActual
Aug 19, 2020
Results delay requested
Aug 19, 2021
Results first posted
Apr 21, 2023
Last update
Apr 21, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 21, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03921411
Lead sponsor
Galderma R&D
Responsible party
Sponsor
First posted
Apr 19, 2019
Start date
Apr 9, 2019
Primary completion
Aug 19, 2020
Completion
Aug 19, 2020
Results posted
Apr 21, 2023
Last update
Apr 21, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Nemolizumab

Start the discussion